Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi's Biosimilars Deal With JHL Confirms Growing Trend In China

Executive Summary

Sanofi is joining the biosimilars trend to tap into China through a local partnership with Taiwan's JHL Biotech, initially focusing on rituximab, a biosimilar product that has great market potential but strong competition in development by domestic peers.

You may also be interested in...

New $350m Site To Build Pfizer’s China Biosimilar Capacity

While some multinationals appear concerned about China's slowing economy and their business prospects in this market, others are forging ahead with major new investments, including Pfizer, which has just unveiled plans for a large biosimilars production and R&D site.

Lilly Builds On Innovent Biologics China Bet

Eli Lilly and Company has expanded its cancer drug collaboration with Chinese biotech Innovent Biologics Inc with plans to develop and market up to three anti-PD-1 based bi-specific antibodies over the next decade, both inside China's expanding healthcare market and abroad.

Oncobiologics raises $31m for biosimilars; RaNA, Ra, SutroVax add VC cash

Smart companies are raising money to advance drug development programs while investors are pouring cash into the biotechnology industry. The latest to raise private capital: Oncobiologics, Ra Pharmaceuticals, RaNA Therapeutics and SutroVax.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts